ReviewFrontiers in oncology2024

Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer.

Qianying Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.